研究リーダーシップのエンパワーメント:臨床試験における腫瘍学先進実務者の参加を支援するための集中講座の開発
Carol Guarnieri1, Gayle Jameson1, Stephanie Franz1
1From HonorHealth Research Institute, Scottsdale, Arizona.
Journal of the advanced practitioner in oncology
|February 16, 2026
まとめ
教育コースでは,臨床研究における主要研究者 (PI) になるために,がん学先進実務者 (OAP) を成功裏に訓練しました. このイニシアチブは,新しいがん治療法を評価するためにより多くのPIの必要性に対応しています.
科学分野:
- 腫瘍学 腫瘍学
- クリニック・リサーチ 臨床研究
- 医療教育 医療教育について
背景:
- 腫瘍学先進実務者 (OAP) はがん治療において不可欠であるが,臨床研究におけるリーダーシップの役割は限られている.
- 新しいがん治療法を評価するために,主要な研究者 (PI) と副研究者 (sub-Is) の必要性が増しています.
研究 の 目的:
- 臨床試験におけるPIの役割のためのOAPを装備するために設計された集中的な教育コースを評価する.
- 臨床研究のリーダーシップに対するOAPの知識,自信,準備に対するコースの影響を評価する.
主な方法:
- HonorHealth Research Institute (HRI) で,21人のOAPのために3.5日間の教育コースが実施されました.
- コースには,講義,医師のラウンドテーブル,プロトコル・シナプス・ワークショップが含まれていました.
- 参加者の知識とコースの影響は,アンケートとフォローアップ調査を通じて評価されました.
主要な成果:
- 講義中の質問の正確さの65%の改善は,知識の獲得を示しています.
- 参加者の100%が学習目標を達成することに同意しました.
- 63%は,メンターとのプロトコルシナプスの草案をレビューし,ほとんどの方が進歩に自信を持っている.
結論:
- この教育コースは,OAPが臨床研究のリーダーシップに移行するための基礎知識を提供しました.
- このプログラムは,がん研究における重要なニーズに対処し,主要な研究者としての役割のためにOAPを成功裏に準備しました.
さらに関連する動画
関連する概念動画
Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Preclinical Development: Overview
6.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.0K
Cancer Survival Analysis
784
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
784
Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K


